X

Trial Profile

A Clinical Trial to Investigate IMA204

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 02 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IMA 204 (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors Immatics N.V.

Most Recent Events

16 Nov 2021 According to an Immatics N.V. media release, company plans to submit IND application for IMA204 is expected in 2022.
09 Sep 2020 New trial record
03 Sep 2020 According to an Immatics N.V. media release, Immatics expects to submit the IND for its fourth ACT program, IMA204, in 2021. This clinical trial will investigate a T cell receptor (TCR) directed against the tumor stroma target, COL6A3, which is highly prevalent in the tumor microenvironment in a broad range of tumor tissues including lung, pancreas, esophagus, breast, ovary, colon and stomach cancer. Immatics expects to provide a data update from the pre-clinical studies in Q3 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com